About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $8.90 | Open | $8.84 |
Volume | 711.9K | Market Cap | 735.98M |
Yield | Last Dividend |
Middle East & Africa Drug Modelling Soft... | 03/01/21 |
The Business Market Insights provides you regional research analysis on ???Middle East & AfricaDrug Modelling Software Market??? and forecast to 2027.... |
Thinking about buying stock in Workhorse... | 02/25/21 |
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, SNDL, NOK, CLVS, and CGEN. To see how InvestorsO... |
Compugen Will stock surge before Earning... | 02/24/21 |
Compugen announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? |
Compugen To Test COM701, Opdivo Combinat... | 02/22/21 |
Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), ??? |
Compugen Does Earnings Surprise History ... | 02/18/21 |
Compugen announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? |
Compugen (NASDAQ:CGEN) Stock Rating Lowe... | 10/22/20 |
Compugen (NASDAQ:CGEN) was downgraded by stock analysts at BidaskClub from a ???buy??? rating to a ???hold??? rating in a research note issued on Wedn... |
Compugen Ltd. (NASDAQ:CGEN) Expected to ... | 10/20/20 |
Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Inv... |
Analysts Set Compugen Ltd. (NASDAQ:CGEN)... | 10/19/20 |
Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of ???Buy??? from the eleven ratings firms that are presently covering the comp... |
Compugen Starts Dosing In Early-Stage Co... | 09/09/20 |
Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers ??... |
We spoke to 3 financial experts, who bro... | 06/11/20 |
With the stock market climbing off multiyear lows, investors are seeking opportunities in a market that's confounded even the top Wall Street strategi... |
Is the Options Market Predicting a Spike... | 05/18/20 |
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately. |
Compugen (CGEN) is a Great Momentum Stoc... | 04/30/20 |
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Thinking about buying stock in Bed Bath ... | 04/16/20 |
NEW YORK, April 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, CGEN, CODX, GE, and TRIP. To see how InvestorsO... |
Compugen Projected to Rise Over 100% in ... | 03/24/20 |
No summary available. |
Compugen prices $75M stock offering | 03/12/20 |
Compugen (NASDAQ:CGEN) has priced its public offering of ~8.3M ordinary shares at $9.00 per share, for expected gross proceeds of ~$75M. Underwriters'... |
A CIO overseeing $230 million explains h... | 01/17/20 |
Gerry Frigon, founder and chief investment officer at Taylor Frigon Capital Management, has found a way to play in the high-risk, high-reward biotechn... |
Compugen Announces Appointment of Dr. Ol... | 01/08/20 |
HOLON, Israel, Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive tar... |
FoxWise Technologies Inc. and Compugen I... | 11/21/19 |
OTTAWA, Ontario & RICHMOND HILL, Ontario--(BUSINESS WIRE)--Compugen Inc. acquires a minority interest in Indigenous IT company FoxWise. |
Compugen (NASDAQ:CGEN) Issues Quarterly ... | 11/12/19 |
Compugen (NASDAQ:CGEN) issued its earnings results on Monday. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus es... |
Compugen (CGEN) Upgraded to Buy: Here's ... | 05/23/19 |
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Compugen Ltd. (CGEN) Q1 2019 Earnings Ca... | 05/20/19 |
CGEN earnings call for the period ending March 31, 2019. |
Compugen Ltd. (CGEN) CEO Anat Cohen-Daya... | 05/20/19 |
No summary available. |
Compugen begins patient dosing in early-... | 05/20/19 |
No summary available. |
Compugen beats by $0.03 | 05/20/19 |
No summary available. |
What Makes Compugen (CGEN) a New Strong ... | 04/18/19 |
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might driv... |
Compugen nabs two new patents in U.S. fo... | 03/12/19 |
No summary available. |
Compugen Ltd. (CGEN) CEO Anat Cohen-Daya... | 02/26/19 |
No summary available. |
Compugen down 8% on Q4 results | 02/26/19 |
No summary available. |
Compugen beats by $0.04 | 02/26/19 |
No summary available. |
ARNC, RNN, EDIT and SDLP among notable m... | 01/22/19 |
No summary available. |
Strong Buy rating | 04/06/21 |
SVB Leerink maintains Outperform rating and lowers Price Target from $19.00 to $16.00 |
Date | 2021-02-25 (BMO) | Est. (EPS/Rev.) | ($0.10)/ 0 |
Actual (EPS/Rev.) | $-0.10/ $2.00 M | EPS (TTM) | 0 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
FEAT. MIGUEL | JOHN KROLIKOWSKI JR | 81.00 % | Subscribe |
Tech Trades | Tech Trades | 81.00 % | Follow |
Options Eagle | George | 78.00 % | Follow |
Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
FEAT. LIL WAYNE | JOHN KROLIKOWSKI JR | 42.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.